Skip to content

Study on the effectiveness of different ways to prevent the adverse reactions of Hemabate during cesarean section under NICaS monitoring

Study on the effectiveness of different ways to prevent the adverse reactions of Hemabate during cesarean section under NICaS monitoring

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000038350
Enrollment
Unknown
Registered
2020-09-21
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia for Cesarean Section

Interventions

Group A:pretreatment with sufentanil 0.1 ug/kg
Group B:Intravenous pump injection of dexmedetomidine 0.8 ug /kg/h pretreatment
Group C: pretreatment with tramadol 0.15 mg/kg
Group D:pretreatment with 0.9% sodium chloride solution

Sponsors

Chongqing Health Center for Women and Children
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: The full-term pregnant women who are planning to undergo cesarean section, aged >= 18 years; American Society of Anesthesiologists (ASA) grade II; There are risk factors for uterine fatigue (such as twins, macrosomia, polyhydramniosetc.). Plan to treated with Hemabate uterine injection; Committed to participate this trail and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Preoperative combined with moderate to severe systemic diseases; 2. Preoperative combined with asthma, severe allergies, hypertension and glaucoma and other prostaglandin contraindications; 3. Preoperative platelet count < 100 x 10^9/L, 4. Refused to participate in this study.

Design outcomes

Primary

MeasureTime frame
nausea and vomiting;chest tightness;dizziness and headache,;

Secondary

MeasureTime frame
Hemodynamic;Sedation score (Ramsay);

Countries

China

Contacts

Public ContactXiang bo

Chongqing Health Center for Women and Children

358276601@qq.com+86 15902352373

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 31, 2026